MyKid-study: efficacy and systemic side effects of intracameral Mydrane® injections in children undergoing cataract surgery.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504173-21-00

Acronym

EDGE1169

Enrollment

Registered

2023-06-30

Start date

2023-07-01

Completion date

2025-09-17

Last updated

2023-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric cataract

Brief summary

Sufficient pupillary dilatation to perform surgery without mechanical dilatation

Detailed description

Hart rate and blood pressure

Interventions

DRUGMydrane 0

DRUG2 mg/ml + 3

DRUG1 mg/ml + 10 mg/ml oplossing voor injectie

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Sufficient pupillary dilatation to perform surgery without mechanical dilatation	—

Secondary

Measure	Time frame
Hart rate and blood pressure	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026